Chronicle Journal: Finance

Bristol-Myers tries to salvage $74 billion deal with Celgene. Meets with investors in NYC, Boston

Bristol-Myers Squibb is meeting with shareholders in Boston and New York as its $74 billion purchase of drugmaker Celgene is at risk of being derailed.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.